1. Introduction

Type 2 diabetes mellitus (T2DM) is a serious condition which is widespread in China, affecting upwards of 10% of the adult population [1, 2]. This disease is multifactorial in nature, arising in a heterogeneous fashion owing to interactions between both genetic and environmental factors [3]. As T2DM is a serious metabolic disease, and mitochondria serve as invaluable metabolic regulators within cells, these organelles are thought to be central to T2DM pathogenesis [4]. As multiple studies have found that T2DM risk can be transmitted in a matrilineal fashion, this further supports the potential for a mitochondrial role in the development of this serious disease [2, 5]. Indeed, some studies have proposed that mutations within mitochondrial tRNA sequences are key factors influencing the development of T2DM and other metabolic diseases [6]. The 3243A>G, m.3264T>C mutations in the tRNA^Leu([UUR]), m.4291T>C mutation in the tRNA^Glu, and m.10003T>C mutation in the tRNA^Gly have all been identified as potential mutations affecting T2Dm disease predisposition [7–12]. Exactly how these mutations ultimately contribute to disease onset, however, remains poorly understood, and as such, there is a clear need for additional research into how mitochondrial dysfunction can act to mediate the onset or progression of T2DM.

During a T2DM genetic screening effort among 100 Chinese subjects, we were able to detect a G-to-A transition at position 15897 in individuals with a familial history of matrilineal T2DM transmission, as well as a set of variants belonging to the Asian haplogroup D4b1. This mutation has been implicated to be important for tRNA identity and stability. Using cybrid cell models, the decreased efficiency of mitochondrial tRNA^Thr levels caused by the m.15897G>A mutation results in respiratory deficiency, protein synthesis and assembly, mitochondrial ATP synthesis, and mitochondrial membrane potential. These mitochondrial dysfunctions caused an increase in the production of reactive oxygen species in the mutant cell lines. These data provide a direct evidence that a novel tRNA mutation was associated with T2DM. Thus, our findings provide a new insight into the understanding of pathophysiology of maternally inherited diabetes.
mitochondrial tRNA<sup>Thr</sup> levels, protein synthesis and assembly, membrane potential, adenosine triphosphate (ATP) production, and reactive oxygen species (ROS) generation.

2. Materials and Methods

2.1. Subjects. We initially recruited a Chinese T2DM proband who was not related at the First Affiliated Hospital of Soochow University, China. After obtaining informed consent, we then conducted clinical evaluations and isolated blood samples from all family members who agreed to participate in this study. Any family or personal history of metabolic disease was identified through thorough historical and physical exams, while proband and family members also underwent blood glucose testing at our hospital. In total, we recruited 104 control Chinese volunteers in order to screen for any mitochondrial tRNA mutations identical to those identified in the family of T2DM patients. The Ethics Committees of Soochow University approved all study protocols. The principles of the Declaration of Helsinki were observed in this study [13].

2.2. Mitochondrial Genome Mutation Analysis. We isolated total genomic and mitochondrial DNA from patient whole blood samples via a DNA Extraction Kit (QIAGEN: 51104). We then conducted PCR amplification of the whole mitochondrial genome of the proband subject with T2DM (SZDM012-III-14), generating 24 overlapping PCR product fragments through the use of primers specific to the light and heavy strands, as in the previous studies [12]. Subsequently, we sequenced the fragments by an ABI 3700 automated DNA instrument and analyzed by comparing to the updated Cambridge consensus sequence (GenBank accession number: NC_012920) [14].

In order to detect the m.15897G>A mutation of the mitochondrial tRNA<sup>Thr</sup> gene, we used the following primers in order to specifically amplify the 15792-31 region of the mitochondrial DNA via PCR: F:5′-TCA TTG GAC AAG TAG CAT CC-3′ and R:5′-GAG TGG TTA ATA GGG TGA TAG-3′, as in the previous studies [11]. We then isolated and assessed these fragments as in the previous reports [12].

2.3. Phylogenetic Analyses. In order to perform interspecific analyses, as in the previous studies, we compared human mtDNA nucleotide variation frequencies to sequences in 16 other species of vertebrates in order to determine the appropriate conservation index (CI) [15, 16]. Based on this CI value, it was then possible to determine what percentage of these 16 species exhibit a conserved wild-type base at the position of interest.

We further used an online application (http://www.mitotoool.org/genomeRSRS.html) in order to determine the mitochondrial haplogroup of the proband and related individuals, consistent with current haplogroup nomenclature [17, 18].

2.4. Cell Culture. The Epstein-Barr virus was used to generate immortalized patient cell lines from the proband patient (III-3) bearing the m.15897G>A mutation, as well as from a control individual (C2). These cells were cultured in RPMI 1640 containing 10% FBS. Cybrid cells were generated by adapting previous protocols. Briefly, bromodeoxyuridine-(BrdU-) resistant 143B.TK-cells were cultured in DMEM containing 5% FBS, and the ρ<sup>0</sup>206 cell line lacking mtDNA derived from these same cells was also grown under these conditions in the presence of 50 μg uridine/ml. The patient and control cell lines were then enucleated and fused with the ρ<sup>0</sup>206 cells. The resultant cybrid cell lines were then selected in uridine-free DMEM supplemented with BrdU, allowing for donor-derived cybrid lines that could then be assessed for the m.15897G>A mutation, amounts of mtDNA, and other cellular genetic features. The resultant cybrid lines were maintained in DMEM containing 5% FBS.

2.5. Mitochondrial tRNA Northern Blotting. For the tRNA Northern blot analysis, total mitochondrial RNAs were isolated as in previous reports [19, 20]. We then electrophoretically separated 2 μg of this mitochondrial RNA onto a nylon membrane (Roche), prior to conducting a hybridization analysis using appropriate oligodeoxynucleotides as probes. We used digoxigenin- (DIG-) labeled probes specific to 5S RNA, tRNA<sup>AB</sup>, tRNA<sup>AC</sup>, tRNA<sup>Thr</sup>, tRNA<sup>Tru</sup>, tRNA<sup>Val</sup> and tRNA<sup>Thi</sup> and then used these for hybridization reactions and subsequent densitometric quantification, as in the previous reports [19, 20]. For the tRNA mobility shift assay, 2 μg of total mitochondrial RNAs was electrophoresed as detailed elsewhere. After electrophoresis, the gels were treated according to the procedure for the tRNA Northern blot analysis described above [19, 20]. Moreover, the ami-noacylation of tRNA assays was performed as detailed previously [19, 20].

2.6. Western Blotting. Western blotting was conducted as in the previous studies [19, 20]. Primary antibodies used herein include those targeting ND6 (Abcam, ab81212), ND4 (Abcam, ab219822), ATP6 (Proteintech, 55313-1-AP), ND1 (Abcam, ab74257), CYB (Proteintech, 55090-1AP), CO2 (Abcam, ab110258), and VDAC (Proteintech, 10866-1-AP). As a secondary detection antibody, we employed the peroxidase AffiniPure goat anti-mouse IgG and goat anti-rabbit IgG (Jackson) constructs, and an enhanced chemiluminescence (ECL) system (Millipore) was used for band detection, after which densitometric calculations were performed.

2.7. Blue Native Electrophoresis Analysis. Blue Native gel electrophoresis (PAGE) was performed by isolating mitochondrial proteins from mutant and control cybrid cell lines as described elsewhere [21]. Samples containing 30 μg of proteins were separated on 3–12% Native PAGE gel. The primary antibodies applied for this experiment were NDUF9 (Abcam, ab128744), SDHA (Abcam, ab14715), UQRC2 (Abcam, ab203832), COX5A (Abcam, ab110262), and ATP5C (Abcam, ab119686). As a secondary detection antibody, an ECL system was used for band detection, after which densitometric calculations were performed as shown in Western blotting.
2.8. Measurements of Enzymatic Activity. The complex I, II, III, and IV activities were assessed as described elsewhere [20].

2.9. Assessment of ATP Levels. We utilized a CellTiter-Glo Luminescent cell viability assay (Promega, G7572) in order to assess levels of mitochondrial ATP based on a modified protocol provided by the manufacturer, with additional previously detailed modifications [20].

2.10. Mitochondrial Membrane Potential Measurement. A JC-10 Mitochondrial Membrane Potential Microplate Assay Kit (Abcam, ab112134) was utilized based on the provided protocols, as in the previous studies, as a means of assessing the mitochondrial membrane potential [20]. Excitation/emission ratios of Ex/Em = 490/590 and 490/525 nm were determined as a means of measuring ΔΨm in samples, with the relative ratio of these two values in mutants and controls being calculated to determine the ΔΨm value.

2.11. ROS Measurements. The MitoSOX Red Mitochondrial Superoxide Indicator (Invitrogen, M36008) was used to assess ROS levels within live cells based on provided protocols, as in the previous studies [22]. ROS production rates were determined based on geometric mean intensities in samples, and ratios of these intensity values between unstimulated and H2O2-stimulated cells were used to determine whether ROS generation changed under oxidative stress conditions.

2.12. Statistical Analysis. Microsoft Excel 2016 was used for all statistical testing, comparing values via unpaired, two-tailed t-tests. P < 0.05 was the threshold of significance unless otherwise indicated.

3. Results

3.1. Familial T2DM Presentation in a Han Chinese Family. We identified a Chinese family SZDM012 that had visited the Diabetes Clinic at the First Affiliated Hospital of Soochow University (as shown in Figure 1). This patient underwent full physical examinations in an effort to identify any clinical or genetic factors associated with this instance of familial T2DM. All patients had been diagnosed with T2DM based on standard diagnostic criteria: (1) fasting plasma glucose ≥ 7 mmol/dL, (2) oral glucose tolerance ≥ 11 mmol/dL (200 mg/dL), or (3) ≥ 6.5% glycated hemoglobin (HbA1c). Patients were diagnosed as having an elevated diabetes risk if they did not have a history of diabetes and met the following criteria: (1) fasting plasma glucose from 5.5-7 mmol/L, (2) 2-hour plasma glucose levels from 0.78-1.11 mmol/dL (140-199 mg/dL), or (3) a HbA1c concentration of 5.7-6.4%. When a total of 10 matrilineal relatives were surveyed, a total of 6 were determined to have T2DM (3 males and 3 females; as shown in Table 1). T2DM symptoms were first diagnosed in these patients at the average age of 57 (range: 43-72), and other matrilineal relatives exhibited an elevated risk of diabetes based on the diagnostic criteria. We did not observe any other significantly abnormal clinical conditions in these related individuals, such as cardiac, muscular, or neurological diseases. No other surveyed members of this family exhibited T2DM, leading to our determination that this family exhibited matrilineally inherited T2DM.
Table 2: mtDNA variants in a Chinese pedigree with T2DM.

| Gene       | Position | Replacement | AA change | Conservation (H/B/M/X)* | Previously reported$^b$ |
|------------|----------|-------------|-----------|-------------------------|-------------------------|
| D-loop     | 73       | A-G         |           | Yes                     |                         |
|            | 263      | A-G         |           | Yes                     |                         |
|            | 310      | T-TC        |           | Yes                     |                         |
|            | 374      | A-G         |           | Yes                     |                         |
|            | 489      | T-C         |           | Yes                     |                         |
|            | 514      | C-Del       |           | Yes                     |                         |
|            | 515      | A-Del       |           | Yes                     |                         |
|            | 16185    | C-T         |           | Yes                     |                         |
|            | 16189    | T-C         |           | Yes                     |                         |
|            | 16223    | C-T         |           | Yes                     |                         |
|            | 16232    | C-A         |           | Yes                     |                         |
|            | 16319    | G-A         |           | Yes                     |                         |
|            | 16362    | T-C         |           | Yes                     |                         |
| 12S rRNA   | 750      | A-G         |           | A/A/A/A/-               | Yes                     |
|            | 1438     | A-G         |           | A/A/A/G                 | Yes                     |
| 16S rRNA   | 2706     | A-G         |           | A/G/A/A                 | Yes                     |
|            | 3010     | G-A         |           | G/G/A/A                 | Yes                     |
| ND2        | 4769     | A-G         |           | Yes                     |                         |
|            | 4883     | C-T         |           | Yes                     |                         |
|            | 5178     | C-A         | Leu-Met   | L/T/T/T                  | Yes                     |
| CO1        | 7028     | C-T         |           | Yes                     |                         |
|            | 7270     | T-C         | Val-Ala   | V/M/M/I                  | No                      |
| CO2        | 8020     | G-A         |           |                         | Yes                     |
| ATP8       | 8414     | C-T         | Leu-Phe   | L/F/M/W                  | Yes                     |
| ATP6       | 8701     | A-G         | Thr-Ala   | T/S/L/Q                  | Yes                     |
|            | 8860     | A-G         | Thr-Ala   | T/A/A/T                  | Yes                     |
| CO3        | 9540     | T-C         |           | Yes                     |                         |
|            | 10136    | A-G         |           | No                      |                         |
| ND3        | 10181    | C-T         |           | Yes                     |                         |
|            | 10398    | A-G         | Thr-Ala   | T/T/T/A                  | Yes                     |
|            | 10400    | C-T         |           | Yes                     |                         |
| ND4        | 10807    | A-G         |           | No                      |                         |
|            | 10873    | T-C         |           | Yes                     |                         |
|            | 11242    | C-T         |           | Yes                     |                         |
|            | 11719    | G-A         |           | Yes                     |                         |
| ND5        | 12705    | C-T         |           | Yes                     |                         |
| ND6        | 14256    | T-C         | Ile-Val   | I/M/I/V                  | No                      |
|            | 14596    | A-G         |           | Yes                     |                         |
|            | 14617    | A-G         |           | No                      |                         |
|            | 14668    | C-T         |           | Yes                     |                         |
| Cytb       | 14766    | C-T         | Thr-Ile   | T/S/T/S                  | Yes                     |
|            | 14783    | T-C         |           | Yes                     |                         |
|            | 15043    | G-A         |           | Yes                     |                         |
|            | 15301    | G-A         |           | Yes                     |                         |
| tRNA Thr   | 15897    | G-A         |           | G/G/G/G                  | No                      |

*Conservation of amino acid for polypeptides or nucleotide for RNAs in human (H), bovine (B), mouse (M), and Xenopus laevis (X). $^b$CRS: Cambridge Reference Sequence. $^c$See online mitochondrial genome databases http://www.mitomap.org.
3.2. Identification of T2DM-Associated Mitochondrial Mutations. We next sequenced the mitochondrial genomes of the proband SZDM012-III-14 patient in an effort to determine whether there were specific mitochondrial mutations underlying the observed matrilineal T2DM pattern of inheritance. After comparing our sequences from this patient to the Cambridge consensus sequence, as shown in Table 2, we detected a total of 46 single nucleotide polymorphisms in the mitochondrial genome and additionally determined their mitochondrial haplogroup to be the Eastern Asian haplogroup D4b1. Of these 46 mutations, 13 were previously described D-loop variants, 2 were known 12S rRNA gene variants, 2 were known 16SrRNA variants, one was the newly characterized m.15897G>A mutation in the tRNA Thr gene (as shown in Figure 2), 27 variants (5 novel and 22 known) including 19 were to be silent variants, and 8 were missense mutations affecting protein-coding genes which were as follows: m.5178C>A(Leu>Met) in the ND2 gene, m.7270T>C(Val-Ala) in the CO1 gene, m.8701A>G(Thr>Ala) and m.8860A>G(Thr>Ala) in the ATP6 gene, m.10398A>G(Thr>Ala) in the ND3 gene, m.14256T>C(Ile>Val) in the ND6 gene, and m.14766C>T(Thr>Ile) in the CYTB gene. These variants were evaluated for the pathogenicity using the following criteria: (1) present in <1% of the controls, (2) evolutionary conservation, and (3) potential structural alterations. We next performed phylogenetic comparisons of these variants to known sequences of these same genes in 16 additional primate species in order to establish to what extent they were conserved. The known missense variants were reported polymorphic variation sites [6]. The two novel variants, CO1 m.7270T>C and ND6 m.14256T>C, revealed lowly evolutionary conservation. Therefore, these two variants were likely to be polymorphic. However, the m.15897G>A mutation in the tRNA Thr gene exhibited highly evolutionary conservation. We also did not detect this m.15897G>A mutation in 100 Chinese control subjects, and we thus found no evidence that any detected mutation other than m.15897G>A was evolutionarily conserved.

3.3. Altered Conformation and Stability Level of tRNA Thr. We tested the conformation of tRNA Thr in vivo by native polyacrylamide gel. As shown in Figure 2(c), electrophoretic patterns demonstrated that the tRNA Thr in three mutant cell lines carrying the m.15897G>A mutation migrated much slower than those of the control cybrid cell lines. In contrast, the levels of the tRNA Ile and tRNA His were similar with the control cybrid cell lines. Furthermore, we found that mutant cell lines exhibited significantly decreased tRNA Thr levels as compared with controls, with the 5S RNA used for normalization within cells (as
Indeed, mutant cells exhibited tRNA-Thr levels which were 51.53\% (P < 0.05) of those in control cells following normalization. For comparison, these mutant cells had steady-state tRNA-Ile, tRNA-His, tRNA-Gln, and tRNA-Ala levels of 99.19\%, 97.45\%, 98.30\%, and 101.78\%, respectively, relative to control cybrid cell lines (as shown in Figure 3).

3.4. Perturbed Aminoacylation of tRNA-Thr. We investigated the aminoacylation properties of carrying m.15897G>A mutation cybrid cell lines. As shown in Figure 4, the efficiencies of aminoacylated tRNA-Thr in the mutant cell lines reflected 11.42\% decrease, relative to the average values of control cell lines. However, the levels of aminoacylation in tRNA-Ile and tRNA-His in mutant cell lines were comparable with those in control cell lines.

3.5. Reduced Mitochondrial Protein Levels. We next assessed the levels of respiratory complex subunits encoded by the mitochondrial DNA via Western blotting, using VDAC to control for equal protein loading. As shown in Figure 5, we found that levels of four proteins generated by mitochondrial translation in mutant cells were present at average levels 71.71\% relative to control cybrid cell lines (P < 0.05). Cells bearing the m.15897G>A mutation also exhibited significant 66.78\%, 74.30\%, 80.74\%, 63.78\%, and 35.31\% reductions in levels of the proteins ND4, ND1, ND6, ATP6, and CO2.
respectively. In contrast, the levels of the CYB protein were not significant with the control cybrid cell lines. However, the levels of polypeptide synthesis in mutant cells showed no significant correlation relative to those in control cells with either the number of codons or the proportion of threonine residues.

3.6. Imbalances in OXPHOS Complexes. We measured the steady-state levels of five OXPHOS complexes by Blue Native gel electrophoresis. As shown in Figure 6, the levels of complex I, complex IV, and complex V in the m.15897G>A mutation cell lines were 52.85%, 70.39%, and 54.93% of the levels observed in control cybrid cell lines, respectively. However, the levels of complexes II and III in the mutant cell lines were comparable with those of three control cell lines.

3.7. Mutation Led to Decreased Complex I and IV Activity. We further assessed the consequences of this m.15897G>A

![Image](https://example.com/image.jpg)
mutation on oxidative phosphorylation using isolated mitochondrial from our mutant and control cybrid cell lines. As shown in Figure 7, we found that complex I and IV activity in the m.15897G>A mutant mitochondria was 70.63%, and 85.68% of the activity observed in control cybrid cell lines (P < 0.05), whereas no changes in complex II/III activity were observed.

3.8. ATP Generation Is Reduced in Mutant Cells. We next assessed how this m.15897G>A influences ATP generation in the mitochondria of affected cells via a luciferin/luciferase assay system. Cells were combined with media containing glucose, with or without oligomycin (to inhibit ATP synthase and promote glycolysis) or a combination of pyruvate and 2-deoxy-d-glucose (to inhibit glycolysis and promote oxidative phosphorylation). As shown in Figure 8, we found that glycolysis activity was comparable between mutant and control cells, whereas ATP production via oxidative phosphorylation was significantly reduced in mutant cybrid cell lines relative to control cybrid cell lines, with ATP production on 70.99% and 75.68% (average 73.37%) that observed in control cells (P = 0.009).

3.9. Mitochondrial Membrane Potential Changes. We next assessed how m.15897G>A mutations altered mitochondrial membrane potential (∆Ψm) with the help of the JC-10 fluorescent probe. As shown in Figure 9, we observed decreased ∆Ψm values in mutant cells bearing the m.15897G>A mutation, with decreases averaging 64.04% of control (63.45% and 64.69%) (P < 0.05). We found that ∆Ψm in mutant cells treated with FCCP were similar to values in control cells.
3.10. Elevated ROS Production. We used flow cytometry to assess ROS production by mutant and control cells but upon H2O2 stimulation and at baseline. As shown in Figure 10, we found that mutant cells bearing the m.15897G>A mutation exhibited increased ROS production, with an average increase of 124.37% (122.45% and 125.67%) relative to control (P < 0.05).

4. Discussion

Herein, we determined that the tRNA<sub>Thr</sub> m.15897G>A mutation is associated with the matrilineal transmission of T2DM risk in a Chinese family. This m.15897G>A mutation affects coding at position 10 of this tRNA, and the presence of a guanine at this position is highly evolutionarily conserved among species, suggesting it is essential for normal tRNA function or pre-tRNA processing [23, 24]. We were only able to detect this mutation in members of a Chinese family exhibiting T2DM, and not in 100 control patients. As shown in Table 1, we observed impaired glucose tolerance in 6 (3 males/3 females) out of a total of 20 matrilineal relatives, compared with the average penetrances of T2DM in other Chinese families carrying the m.10003T>C and m.14692A>G mutation [11, 12]. Average age of diabetes onset in those with the m.15897G>A mutation was 57 (range: 43–72), while the average ages in those families with m.10003T>C and m.14692A>G mutations were 45 and 60 years, respectively [11, 12]. As families with identical m.15897G>A mutations exhibit significant variability, this suggests that nuclear genes and environmental factors (such as diet, BMI, and physical activity) also play a role in modifying phenotypic manifestations of T2DM in these individuals.

The observed mutation located in the 15897 position at a highly conserved nucleotide (conventional position 10) of tRNA<sub>Thr</sub>, where the position is important for the stability and identity of tRNA. The anticipated destabilization of base pairing (10G-25C) by the m.15897G>A mutation may affect secondary structure and function of this tRNA, as in the cases of tm.10003T>C and m.14692A>G mutations [11, 12]. We were able to utilize cell lines bearing this m.15897G>A mutation to provide clear evidence of multiple forms of mitochondrial dysfunction in these cells. For one, we found tRNA<sub>Thr</sub> levels to be clearly decreased in these mutant cells relative to controls (51.53%). Furthermore, the altered tertiary structure caused by the m.15897G>A mutation may perturb the
aminoacylation of tRNA\textsuperscript{Thr} by either charging inefficiently or mischarging with mitochondrial threonyl-tRNA synthetase. It is possible that this mutated form of tRNA\textsuperscript{Thr} has less metabolic stability, resulting in its more rapid degradation and thus reducing effective levels of the tRNA, as in the case of the of tRNA\textsuperscript{Zea(UUR)} m.3243A>G mutation in [25, 26]. This mutation was linked to significant reductions in 7 mitochondrially encoded proteins, leading to incomplete fully assembled OXPHOS complexes, and all of these reductions were associated with a marked reduction in ATP synthesis, as well as increased oxidative stress that may be linked to defects in normal energetic processes. The observed 26.63% decrease in mitochondrial ATP by cells bearing the m.15897G>A mutation was similar to that in cells with the m.14692A>G mutation [11]. Impaired respiratory chain activity can also result in impaired mitochondrial membrane potential, which is closely linked to cell viability, and we found clear reductions in this potential by roughly 35.96% in mutant cells. Moreover, we observed a ~28.29% reduction in mitochondrial protein levels in cells bearing this mutation, and these cells also exhibited altered complex I/IV enzymatic activity which may coincide with increased electron leakage and elevated ROS production. These defective mitochondrial activities were associated with excessive ROS generation in mutant cells, with a roughly 24.37% increase relative to controls. ROS production can in turn result in substantial damage to proximal proteins and other macromolecules, thereby impairing cell functionality.

In conclusion, our work is the first to detect a link between the m.15897G>A mutation and T2DM. Disrupted normal metabolism for this tRNA as a result of this mutation appears to significantly impair normal mitochondrial functionality, with impaired mitochondrial protein synthesis, mitochondrial complex enzymatic activity, membrane potential, ATP production, and ROS generation. As such, this m.15897G>A mutation is clearly a relevant candidate biomarker for heritable T2DM risk, making it useful for molecular diagnostics. Our results therefore have the potential to improve current understanding of T2DM, offering new insights into disease development and suggesting potential avenues for treatment (such as antioxidation therapy) or prevention.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

The authors declare that they have no competing interest.

Authors’ Contributions

Ke Li, Lijun Wu, and Jianjiang Liu have equally contributed to this work.

Acknowledgments

This work was supported by the Project of Natural Science Research in Universities of Jiangsu Province (16KJB320010), the Suzhou Science and Education Program for Promoting Health (KJWX2016015), and the 2019 Suzhou City Health Young Talent “National Tutor System” Training Program.

References

[1] D. Meetoo, P. McGovern, and R. Safadi, “An epidemiological overview of diabetes across the world,” The British Journal of Nursing, vol. 16, no. 16, pp. 1002–1007, 2007.
[2] Y. Xu, L. Wang, J. He et al., “Prevalence and control of diabetes in Chinese adults,” Journal of the American Medical Association, vol. 310, no. 9, pp. 948–959, 2013.
[3] K. R. Owen and M. I. McCarthy, “Genetics of type 2 diabetes,” Current Opinion in Genetics & Development, vol. 17, no. 3, pp. 239–244, 2007.
[4] F. Thomas, B. Balkau, F. Vauzelle-Kervroedan, and L. Papoz, “Maternal effect and familial aggregation in NIDDMD. The CODIAB Study. CODIAB-INSERM-ZENECA Study Group,” Diabetes, vol. 43, no. 1, pp. 63–67, 1994.
[5] R. W. Taylor and D. M. Turnbull, “Mitochondrial DNA mutations in human disease,” Nature Reviews Genetics, vol. 6, no. 5, pp. 389–402, 2005.
[6] M. T. Lott, J. N. Leipzig, O. Derbeneva et al., “mtDNA variation and analysis using Mitomap and Mitomaster,” Current Protocols in Bioinformatics, vol. 44, pp. 1.23.1–1.23.26, 2013.
[7] J. M. van den Ouweland, H. H. Lemkes, W. Ruitenbeek et al., “Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness,” Nature Genetics, vol. 1, no. 5, pp. 368–371, 1992.
[8] M. E. Damore, P. W. Speiser, A. E. Slonim et al., “Early onset of diabetes mellitus associated with the mitochondrial DNA T14709C point mutation: patient report and literature review,” Journal of Pediatric Endocrinology & Metabolism, vol. 12, no. 2, pp. 207–213, 1999.
[9] Y. Suzuki, S. Suzuki, Y. Hinokio et al., “Diabetes associated with a novel 3264 mitochondrial tRNA(Leu)(UUR) mutation,” Diabetes Care, vol. 20, no. 7, pp. 1138–1140, 1997.
[10] F. H. Wilson, A. Hariri, A. Farhi et al., “A cluster of metabolic defects caused by mutation in a mitochondrial tRNA,” Science, vol. 306, no. 5699, pp. 1190–1194, 2004.
[11] M. Wang, H. Liu, J. Zheng et al., “A deafness- and diabetes-associated tRNA mutation causes deficient pseudouridinylation at position 55 in tRNAGlu and mitochondrial dysfunction,” The Journal of Biological Chemistry, vol. 291, no. 40, pp. 21029–21041, 2016.
[12] H. Liu, R. Li, W. Li et al., “Maternally inherited diabetes is associated with a homoplasmic T10003C mutation in the mitochondrial tRNA\textsuperscript{26S} gene,” Mitochondrion, vol. 21, pp. 49–57, 2015.
[13] A. S. Skierka and K. B. Michels, “Ethical principles and placebo-controlled trials - interpretation and implementation of the Declaration of Helsinki’s placebo paragraph in medical research,” BMC Medical Ethics, vol. 19, no. 1, p. 24, 2018.
[14] M. J. Rieder, S. L. Taylor, V. O. Tobe, and D. A. Nickerson, “Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human
mitochondrial genome,” *Nucleic Acids Research*, vol. 26, no. 4, pp. 967–973, 1998.

[15] Y. Ji, L. Qiao, X. Liang et al., “Leber’s hereditary optic neuropathy is potentially associated with a novel m.5587T>C mutation in two pedigrees,” *Molecular Medicine Reports*, vol. 16, no. 6, pp. 8997–9004, 2017.

[16] M. Woischnik and C. T. Moraes, “Pattern of organization of human mitochondrial pseudogenes in the nuclear genome,” *Genome Research*, vol. 12, no. 6, pp. 885–893, 2002.

[17] S. Xie, J. Zhang, J. Sun et al., “Mitochondrial haplogroup D4j specific variant m.11696G > a(MT-ND4) may increase the penetrance and expressivity of the LHON-associated m.11778G > a mutation in Chinese pedigrees,” *Mitochondrial DNA Part A*, vol. 28, no. 3, pp. 434–441, 2017.

[18] M. Tanaka, V. M. Cabrera, A. M. González et al., “Mitochondrial genome variation in eastern Asia and the peopling of Japan,” *Genome Research*, vol. 14, no. 10A, pp. 1832–1850, 2004.

[19] M. Zhou, L. Xue, Y. Chen et al., “A hypertension-associated mitochondrial DNA mutation introduces an m1G37 modification into tRNAMet, altering its structure and function,” *The Journal of Biological Chemistry*, vol. 293, no. 4, pp. 1425–1438, 2018.

[20] Z. Jia, Y. Zhang, Q. Li et al., “A coronary artery disease-associated tRNA Thr mutation altered mitochondrial function, apoptosis and angiogenesis,” *Nucleic Acids Research*, vol. 47, no. 4, pp. 2056–2074, 2019.

[21] I. Wittig, H. P. Braun, and H. Schägger, “Blue native PAGE,” *Nature Protocols*, vol. 1, no. 1, pp. 418–428, 2006.

[22] P. G. Winyard, B. Ryan, P. Eggleton et al., “Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease,” *Biochemical Society Transactions*, vol. 39, no. 5, pp. 1226–1232, 2011.

[23] J. A. Abbott, C. S. Francklyn, and S. M. Robey-Bond, “Transfer RNA and human disease,” *Frontiers in Genetics*, vol. 5, p. 158, 2014.

[24] J. W. Yarham, J. L. Elson, E. L. Blakely, R. McFarland, and R. W. Taylor, “Mitochondrial tRNA mutations and disease,” *Wiley Interdisciplinary Reviews: RNA*, vol. 1, no. 2, pp. 304–324, 2010.

[25] J. Zhu, P. Yang, X. Liu et al., “The clinical characteristics of patients with mitochondrial tRNA Leu(UUR)m.3243A > G mutation: compared with type 1 diabetes and early onset type 2 diabetes,” *Journal of Diabetes and its Complications*, vol. 31, no. 8, pp. 1354–1359, 2017.

[26] R. Murphy, D. M. Turnbull, M. Walker, and A. T. Hattersley, “Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation,” *Diabetic Medicine*, vol. 25, no. 4, pp. 383–399, 2008.